Compare Dolby Laboratories, Inc. (DLB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.91 (market cap $5.75B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 14.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.35%). Which is the better fit depends on your goals.
| DLB | REGN | |
|---|---|---|
Market Cap | $5.75B | $82.06B |
Sector | Industrials | Health |
52-Week High | $75.62 | $812.27 |
52-Week Low | $48.51 | $555.51 |
Enterprise Value | $5.12B | $76.77B |
Dividend Yield | 2.35% | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
